image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Latest issue now available

SIGN UP NOW
Secondary Recommendation

Craneware - Billing software firm sees huge US healthcare opportunity

October 2008

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • CRW
  • Price:
  • 222p
Critics have often slammed the NHS for its bureaucratic wastage but it seems we are not alone in this problem, with a recent study in the USA concluding that billing errors have led to its Government overpaying its hospitals to the tune of US$23 bn. in recent years. In response, it has sought to reduce this through forcing hospitals to adopt more efficient automated systems to replace antiquated manual ones and this backdrop explains why Craneware (Not listed in FT), which provides billing and auditing software for the US healthcare market, is one of the few recent issues to have performed so well. After being placed by broker KBC Peel Hunt at 128p last September, in a float that raised £5m new money as well as allowing its VC backers t ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Related Articles

Craneware (September 2013)
Craneware (November 2012)
Craneware - Second downgrade this year (August 2012)
Craneware (March 2012)
Craneware (November 2011)
Craneware - New contract wins (September 2011)
Craneware - Acquistion raises forecasts (April 2011)
Craneware - Another amazing share price spike (December 2010)
Craneware - Shares spike vertically by over £1 (October 2010)
Craneware (June 2010)
Craneware - Billing software firm enjoying quick-fire growth (February 2010)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X